II LISA

IV lisa 2. osa muudetakse järgmiselt.

Tabelit 1.2 muudetakse järgmiselt:

koodi P210 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

Čuvati odvojeno od topline, vrućih površina, iskri, otvorenih plamena i ostalih izvora paljenja. Ne pušiti.”

koodi P223 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

Spriječiti dodir s vodom.”

koodi P244 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

Spriječiti dodir ventila i spojnica s uljem i masti.”

koodi P251 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

Ne bušiti, niti paliti čak niti nakon uporabe.”

koodi P284 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

[U slučaju nedovoljne ventilacije] nositi sredstva za zaštitu dišnog sustava.”

Tabelit 1.3 muudetakse järgmiselt:

koodi P310 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

Odmah nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…”

koodi P311 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

Nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…”

koodi P312 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

U slučaju zdravstvenih tegoba nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…”

koodi P340 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

Premjestiti osobu na svježi zrak i postaviti ju u položaj koji olakšava disanje.”

koodi P352 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

Oprati velikom količinom vode/…”

koodi P361 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

Odmah skinuti svu zagađenu odjeću.”

koodi P362 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

Skinuti zagađenu odjeću.”

koodi P364 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

I oprati je prije ponovne uporabe.”

koodi P378 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

Za gašenje rabiti …”

kombineeritud koodide P301 + P310 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

AKO SE PROGUTA: odmah nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…”

kombineeritud koodide P301 + P312 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

AKO SE PROGUTA: u slučaju zdravstvenih tegoba nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…”

kombineeritud koodide P302 + P352 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

U SLUČAJU DODIRA S KOŽOM: oprati velikom količinom vode/…”

kombineeritud koodide P303 + P361 + P353 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

U SLUČAJU DODIRA S KOŽOM (ili kosom): odmah skinuti svu zagađenu odjeću. Isprati kožu vodom/tuširanjem.”

kombineeritud koodide P304 + P340 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

AKO SE UDIŠE: premjestiti osobu na svježi zrak i postaviti ju u položaj koji olakšava disanje.”

kombineeritud koodide P308 + P311 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

U SLUČAJU izloženosti ili sumnje na izloženost: nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…”

kombineeritud koodide P342 + P311 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

Pri otežanom disanju: nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…”

kombineeritud koodide P361 + P364 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

Odmah skinuti svu zagađenu odjeću i oprati je prije ponovne uporabe.”

kombineeritud koodide P362 + P364 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

Skinuti zagađenu odjeću i oprati je prije ponovne uporabe.”

kombineeritud koodide P370 + P378 puhul lisatakse iirikeelse (GA) kande järele järgmine kanne:

„HR

U slučaju požara: za gašenje rabiti …”

III LISA

VI lisa 3. osa muudetakse järgmiselt.

Tabelit 3.1 muudetakse järgmiselt:

a)	jäetakse välja kanne indeksinumbriga 015–188-00-X;

kanded indeksinumbritega 006–086-00–6, 015–154-00–4, 015–192-00–1, 601–023-00–4, 601–026-00–0, 603–061-00–7, 605–001-00–5, 605–008-00–3 ja 616–035-00–5 asendatakse järgmiste kannetega:

„006–086-00–6	fenoxycarb (ISO); ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate	276–696-7	72490-01–8	Carc. 2 Aquatic Acute 1 Aquatic Chronic 1	H351 H400 H410	GHS08 GHS09 Wng	H351 H410		M = 1 M = 10 000
015–154-00–4	ethephon; 2-chloroethylphosphonic acid	240–718-3	16672-87–0	Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 Skin Corr. 1C Aquatic Chronic 2	H311 H332 H302 H314 H411	GHS06 GHS05 GHS09 Dgr	H311 H332 H302 H314 H411	EUH071
015–192-00–1	tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate	432–770-2	139189-30–3	Skin Sens. 1	H317	GHS07 Wng	H317
601–023-00–4	ethylbenzene	202–849-4	100–41-4	Flam. Liq. 2 Acute Tox. 4* STOT RE 2 Asp. Tox. 1	H225 H332 H373 (kuulmiselundid) H304	GHS02 GHS07 GHS08 Dgr	H225 H332 H373 (kuulmiselundid) H304
601–026-00–0	styrene	202–851-5	100–42-5	Flam. Liq. 3 Repr. 2 Acute Tox. 4* STOT RE 1 Skin Irrit. 2 Eye Irrit. 2	H226 H361d H332 H372 (kuulmiselundid) H315 H319	GHS02 GHS08 GHS07 Dgr	H226 H361d H332 H372 (kuulmiselundid) H315 H319		*	D
603–061-00–7	tetrahydro-2-furylmethanol; tetrahydrofurfuryl alcohol	202–625-6	97–99-4	Repr. 1B Eye Irrit. 2	H360Df H319	GHS08 GHS07 Dgr	H360Df H319
605–001-00–5	formaldehyde …%	200–001-8	50–00-0	Carc. 1B Muta. 2 Acute Tox. 3* Acute Tox. 3* Acute Tox. 3* Skin Corr. 1B Skin Sens. 1	H350 H341 H301 H311 H331 H314 H317	GHS08 GHS06 GHS05 Dgr	H350 H341 H301 H311 H331 H314 H317		* Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 5 % ≤ C < 25 % Eye Irrit. 2; H319: 5 % ≤ C < 25 % STOT SE 3; H335: C ≥ 5 % Skin Sens. 1; H317: C ≥ 0,2 %	B, D
605–008-00–3	acrolein; prop-2-enal; acrylaldehyde	203–453-4	107–02-8	Flam. Liq. 2 Acute Tox. 1 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1	H225 H330 H300 H311 H314 H400 H410	GHS02 GHS06 GHS05 GHS09 Dgr	H225 H330 H300 H311 H314 H410	EUH071	Skin Corr. 1B; H314: C ≥ 0,1 % M = 100 M = 1	D
616–035-00–5	cymoxanil (ISO); 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide	261–043-0	57966-95–7	Repr. 2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H361fd H302 H373 (veri, harkelund) H317 H400 H410	GHS08 GHS07 GHS09 Wng	H361fd H302 H373 (veri, harkelund) H317 H410		M = 1 M = 1”

järgmised kanded lisatakse vastavalt tabelis 3.1 esitatud kannete järjekorrale:

„050–028-00–2	2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate	260–829-0	57583-35–4	Repr. 2 Acute Tox. 4 STOT RE 1 Skin Sens. 1 A	H361d H302 H372 (närvisüsteem, immuunsüsteem) H317	GHS08 GHS07 Dgr	H361d H302 H372 (närvisüsteem, immuunsüsteem) H317
050–029-00–8	dimethyltin dichloride	212–039-2	753–73-1	Repr. 2 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 STOT RE 1 Skin Corr. 1B	H361d H330 H301 H311 H372 (närvisüsteem, immuunsüsteem) H314	GHS08 GHS06 GHS05 Dgr	H361d H330 H301 H311 H372 (närvisüsteem, immuunsüsteem) H314	EUH071
601–088-00–9	4-vinylcyclohexene	202–848-9	100–40-3	Carc. 2	H351	GHS08 Wng	H351
601–089-00–4	muscalure; cis-tricos-9-ene	248–505-7	27519-02–4	Skin Sens. 1B	H317	GHS07 Wng	H317
604–090-00–8	4-tert-butylphenol	202–679-0	98–54-4	Repr. 2 Skin Irrit. 2 Eye Dam. 1	H361f H315 H318	GHS08 GHS05 Dgr	H361f H315 H318
604–091-00–3	etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether	407–980-2	80844-07–1	Lact. Aquatic Acute 1 Aquatic Chronic 1	H362 H400 H410	GHS09 Wng	H362 H410		M = 100 M = 1 000
606–146-00–7	tralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one	—	87820-88–0	Carc. 2 Acute Tox. 4 Aquatic Chronic 2	H351 H302 H411	GHS08 GHS07 GHS09 Wng	H351 H302 H411
606–147-00–2	cycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one	405–230-9	101205-02–1	Repr. 2	H361d	GHS08 Wng	H361d
607–705-00–8	benzoic acid	200–618-2	65–85-0	STOT RE 1 Skin Irrit. 2 Eye Dam. 1	H372 (kopsud) (sissehingamine) H315 H318	GHS08 GHS05 Dgr	H372 (kopsud) (sissehingamine) H315 H318
607–706-00–3	methyl 2,5-dichlorobenzoate	220–815-7	2905-69–3	Acute Tox. 4 STOT SE 3 Aquatic Chronic 2	H302 H336 H411	GHS07 GHS09 Wng	H302 H336 H411
612–287-00–5	fluazinam (ISO); 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine	—	79622-59–6	Repr. 2 Acute Tox. 4 Eye Dam. 1 Skin Sens. 1 A Aquatic Acute 1 Aquatic Chronic 1	H361d H332 H318 H317 H400 H410	GHS08 GHS07 GHS05 GHS09 Dgr	H361d H332 H318 H317 H410		M = 10 M = 10
613–317-00-X	penconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole	266–275-6	66246-88–6	Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1	H361d H302 H400 H410	GHS08 GHS07 GHS09 Wng	H361d H302 H410		M = 1 M = 1
613–318-00–5	fenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate	—	473798-59–3	Aquatic Chronic 2	H411	GHS09	H411
616–212-00–7	3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate	259–627-5	55406-53–6	Acute Tox. 3 Acute Tox. 4 STOT RE 1 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H331 H302 H372 (kõri) H318 H317 H400 H410	GHS06 GHS08 GHS05 GHS09 Dgr	H331 H302 H372 (kõri) H318 H317 H410		M = 10 M = 1”

Tabelit 3.2 muudetakse järgmiselt:

a)	jäetakse välja kanne indeksinumbriga 015–188-00-X;

kanded indeksinumbritega 006–086-00–6, 015–154-00–4, 015–192-00–1, 601–023-00–4, 601–026-00–0, 603–061-00–7, 605–001-00–5 ja 616–035-00–5 asendatakse järgmiste kannetega:

„006–086-00–6	fenoxycarb (ISO);ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate	276–696-7	72490-01–8	Carc. Cat. 3; R40 N; R50-53	Xn; N R: 40–50/53 S: (2-)22–36/37–60-61	N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 %
015–154-00–4	ethephon; 2-chloroethylphosphonic acid	240–718-3	16672-87–0	C; R34 Xn; R20/21/22 N; R51-53	C; N R: 20/21/22–34-51/53 S: (1/2-)26–36/37/39–45-61	Xi; R37: 5 % ≤ C < 10 %
015–192-00–1	tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate	432–770-2	139189-30–3	R43	Xi R: 43 S: (2-)24–37
601–023-00–4	ethylbenzene	202–849-4	100–41-4	F; R11 Xn; R20-48/20–65	F; Xn R: 11–20-48/20–65 S: (2-)16–24/25–29-62
601–026-00–0	styrene	202–851-5	100–42-5	Repr. Cat. 3; R63 Xn; R20-48/20 Xi; R36/38 R10	Xn R: 10–20-36/38–48/20–63 S: (2-)23–36/37–46	Xn; R20: C ≥ 12,5 % Xi; R36/38: C ≥ 12,5 %	D
603–061-00–7	tetrahydro-2-furylmethanol; tetrahydrofurfuryl alcohol	202–625-6	97–99-4	Repr. Cat. 2; R61 Repr. Cat. 3; R62 Xi; R36	T R: 36–61-62 S: 45–53	Xi; R36: C ≥ 10 %
605–001-00–5	formaldehyde …%	200–001-8	50–00-0	Carc. Cat. 2; R45 Muta. Cat. 3; R68 T; R23/24/25 C; R34 R43	T R: 23/24/25–34-43–45-68 S: 45–53	T; R23/24/25: C ≥ 25 % Xn; R20/21/22: 5 % ≤ C < 25 % C; R34: C ≥ 25 % Xi; R36/37/38: 5 % ≤ C < 25 % R43: C ≥ 0,2 %	B, D
616–035-00–5	cymoxanil (ISO); 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide	261–043-0	57966-95–7	Repr. Cat. 3; R62-63 Xn; R22-48/22 R43 N; R50-53	Xn; N R: 22–43-48/22–62-63–50/53 S: (2-)36/37–46-60–61	N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 %”

järgmised kanded lisatakse vastavalt tabelis 3.2 esitatud kannete järjekorrale:

„050–028-00–2	2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate	260–829-0	57583-35–4	Repr. Cat. 3; R63 T; R48/25 Xn; R22 R43	T R: 22–43-48/25–63 S: (1/2-)36/37–45
050–029-00–8	dimethyltin dichloride	212–039-2	753–73-1	Repr. Cat. 3; R63 T+; R26 T; R24/25–48/25 C; R34	T+ R: 24/25–26-34–48/25–63 S: (1/2-)26–28-36/37/39–45-63
601–088-00–9	4-vinylcyclohexene	202–848-9	100–40-3	Carc. Cat. 3; R40	Xn R: 40 S: (2-)36/37
601–089-00–4	muscalure; cis-tricos-9-ene	248–505-7	27519-02–4	R43	Xi R: 43 S: (2-)24–37
604–090-00–8	4-tert-butylphenol	202–679-0	98–54-4	Repr. Cat. 3; R62 Xi; R38-41	Xn R: 38–41-62 S: (2-)26–36/37/39–46
604–091-00–3	etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether	407–980-2	80844-07–1	R64 N; R50-53	N R: 50/53–64 S: 60–61	N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 %
606–146-00–7	tralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one	—	87820-88–0	Carc. Cat. 3; R40 Xn; R22 N; R51-53	Xn; N R: 22–40-51/53 S: (2-)36/37–60-61
606–147-00–2	cycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one	405–230-9	101205-02–1	F; R11 Repr. Cat. 3; R63	F; Xn R: 11–63 S: (2-)16–36/37–46
607–705-00–8	benzoic acid	200–618-2	65–85-0	T; R48/23 Xi; R38-41	T R: 38–41-48/23 S: (1/2-)26–39-45–63
607–706-00–3	methyl 2,5-dichlorobenzoate	220–815-7	2905-69–3	Xn; R22 N; R51-53	Xn; N R: 22–51/53 S: (2-) 46–61
612–287-00–5	fluazinam (ISO); 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine	—	79622-59–6	Repr. Cat. 3; R63 Xn; R20 Xi; R41 R43 N; R50-53	Xn; N R: 20–41-43–50/53–63 S: (2-)26–36/37/39–46-60–61	N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 %
613–317-00-X	penconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole	266–275-6	66246-88–6	Repr. Cat. 3; R63 Xn; R22 N; R50-53	Xn; N R: 22–50/53–63 S: (2-) 36/37–46-60–61	N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 %
613–318-00–5	fenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate	—	473798-59–3	N; R51-53	N R: 51/53 S: 60–61
616–212-00–7	3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate	259–627-5	55406-53–6	T; R23-48/23 Xn; R22 Xi; R41 R43 N; R50	T; N R: 22–23-41–43-48/23–50 S: (1/2-)24–26-37/39–45-63	N; R50: C ≥ 2,5 %”